Immunosuppressive therapies after intestinal transplant modulate the expression of Th1 signature genes during acute cellular rejection. Implications in the search for rejection biomarkers

Zambernardi, Agustina; Chiodetti, Ana L.; Meier, Dominik; Cabanne, Ana; Nachman, Fabio; Solar, Héctor; Rumbo, Carolina; Gondolesi, Gabriel; Rumbo, Martı́n

doi:10.1111/ctr.12464

Cited by 7 publications

(2 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, in the later period of the acute allograft rejection progress, the increased IP-10 levels combined with the decreased TARC expression revealed that the T H 1 chemokines obtain an advantage due to the antagonistic relationship between the chemokines secreted by T H 1 and T H 2 cells. This inference is consistent with the results in a previous report that IP-10 gradually became the protagonist during the acute allograft rejection progress [32]. …”

Section: Discussionsupporting

confidence: 94%

Alterations of Serum IP-10 and TARC in Patients with Early Acute Rejection after Liver Transplantation

Meng¹,

Gao²,

Tang³

et al. 2017

Cell Physiol Biochem

View full text Add to dashboard Cite

Background/Aims: To analyze alterations of interferon-γ-induced protein 10 (IP-10) and thymus and activation-regulated chemokine (TARC) levels in early acute liver transplantation rejection. Methods: Thirty-six patients with early acute liver transplantation rejection were classified as non-, mild, moderate, and severe rejection groups. The levels of serum IP-10 and TARC were determined on days 3, 2, 1, and 0 before biopsy. Results: The IP-10 activities in all rejection groups were significantly higher (p < 0.05) than those in the non-rejection group at all time points and correlated with the extent of rejection (p < 0.05). The differences in TARC among the three rejection groups were significant (p < 0.05), and its highest level was found in the mild rejection group at all observed time points, whereas its lowest level was detected in the severe rejection group. The analysis of the TARC/IP-10 ratio revealed that the volume was correlated with the rejection degree. This ratio in the moderate and severe rejection groups on days 2, 1, and 0 before biopsy were 20% lower than that before transplantation. Conclusion: Serum IP-10 showed an increasing trend during early acute liver transplantation rejection. IP-10 increase or TARC/IP-10 ratio decrease combining with abnormal hepatic enzymatic alteration could be a valuable and specific sign for early rejection of the transplanted liver.

show abstract

Section: Discussionsupporting

confidence: 94%

Alterations of Serum IP-10 and TARC in Patients with Early Acute Rejection after Liver Transplantation

Meng¹,

Gao²,

Tang³

et al. 2017

Cell Physiol Biochem

View full text Add to dashboard Cite

show abstract

“…A reason for the paucity of clinical studies may be the perceived confounding effect of immunosuppression (tolerance induction regimens, maintenance immunosuppression) and its impact on the kinetics of various biomolecules [86,87], adding to all the other causes of heterogeneity encountered in a clinical setting. Indeed, a clinical study found that, whereas the expression of intragraft IFN-gamma, CXCL10, and CXCL11 was clearly increased during rejection, rejecting individuals receiving reduced immunosuppression showed a 13-fold increase in IFN-gamma expression and a 9-fold increase in CXCL10 expression, while patients with more intense immunosuppression revealed a significantly lower increase [88].…”

Section: Markers Of Local and Systemic Immunologic And Inflammatory A...mentioning

confidence: 99%

Intestinal Transplant Immunology and Intestinal Graft Rejection: From Basic Mechanisms to Potential Biomarkers

Rumbo

Oltean

2023

IJMS

Self Cite

View full text Add to dashboard Cite

Intestinal transplantation (ITx) remains a lifesaving option for patients suffering from irreversible intestinal failure and complications from total parenteral nutrition. Since its inception, it became obvious that intestinal grafts are highly immunogenic, due to their high lymphoid load, the abundance in epithelial cells and constant exposure to external antigens and microbiota. This combination of factors and several redundant effector pathways makes ITx immunobiology unique. To this complex immunologic situation, which leads to the highest rate of rejection among solid organs (>40%), there is added the lack of reliable non-invasive biomarkers, which would allow for frequent, convenient and reliable rejection surveillance. Numerous assays, of which several were previously used in inflammatory bowel disease, have been tested after ITx, but none have shown sufficient sensibility and/or specificity to be used alone for diagnosing acute rejection. Herein, we review and integrate the mechanistic aspects of graft rejection with the current knowledge of ITx immunobiology and summarize the quest for a noninvasive biomarker of rejection.

show abstract

Postoperative Care of the Intestinal Recipient: Graft Monitoring, Nutrition, and Management of Medical Complications

Venick¹,

Cheng²

2018

Solid Organ Transplantation in Infants and Children

View full text Add to dashboard Cite

Immunosuppressive therapies after intestinal transplant modulate the expression of Th1 signature genes during acute cellular rejection. Implications in the search for rejection biomarkers

Abstract: Gene expression of Th1 response mediators is higher during ACR. Triple IS group showed significantly lower expression of pro-inflammatory Th1 mediators during mild ACR indicating that use of these markers to monitor rejection can be affected by the IS treatment used.

Cited by 7 publications

References 26 publications

Alterations of Serum IP-10 and TARC in Patients with Early Acute Rejection after Liver Transplantation

Alterations of Serum IP-10 and TARC in Patients with Early Acute Rejection after Liver Transplantation

Intestinal Transplant Immunology and Intestinal Graft Rejection: From Basic Mechanisms to Potential Biomarkers

Postoperative Care of the Intestinal Recipient: Graft Monitoring, Nutrition, and Management of Medical Complications

Contact Info

Product

Resources

About